Cipla Limited (CIPLA)
🎯 Key Takeaways
- Cipla is in a mature growth phase with stable financials and strategic focus on high-value therapeutic areas like respiratory, oncology, and biosimilars. Despite a recent 1-year return of -9.
- Revenue declined 6.8% QoQ to ₹7,074 in Q3FY26.
- ⚠️ Margin pressure is emerging due to strategic R&D investments and potential pricing or volume softness in core segments, as seen in OPM decline from 28
📖 The Story
Cipla is in a mature growth phase with stable financials and strategic focus on high-value therapeutic areas like respiratory, oncology, and biosimilars. Despite a recent 1-year return of -9.54%, the company demonstrates consistent profitability and strong governance, supported by leadership continuity and ESG compliance. Its narrative centers on disciplined capital allocation, sustainable dividend policy, and long-term R&D investment rather than aggressive expansion.
📰 What's Happening
In the latest filings, Cipla declared a final dividend of ₹13 per share for FY 2025-26, subject to shareholder approval at its 90th AGM scheduled for 25 June 2026, with payment to occur within 7 working days but not later than 30 days from the meeting. The company re-appointed Adil Zainulbhai as director and appointed B S R & Co. LLP as statutory auditor for a 5-year term, underscoring governance stability. Additionally, Cipla released its Business Responsibility and Sustainability Report for FY 2025-26 on 1 June 2026, reaffirming its commitment to ESG transparency and renewable energy usage (84% in India).
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6,163 | 6,694 | 7,051 | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 |
| Operating Profit | 1,565 | 1,876 | 2,076 | 2,211 | 1,827 | 2,037 | 2,164 | 1,185 |
| OPM % | 21.4% | 25.6% | 26.7% | 28.1% | 22.9% | 25.6% | 25.0% | 17.7% |
| Net Profit | 932 | 1,175 | 1,305 | 1,575 | 1,214 | 1,292 | 1,353 | 674 |
| EPS | ₹11.63 | ₹14.58 | ₹16.13 | ₹19.45 | ₹15.13 | ₹16.07 | ₹16.73 | ₹8.37 |
Quarterly revenue has shown modest growth, rising from ₹6,163 crores in Q4FY24 to ₹7,074 crores in Q3FY26, but operating profit and margins have declined recently — OPM fell from a peak of 28.1% in Q3FY25 to 17.7% in Q3FY26. This margin compression aligns with management's strategic shift toward higher-R&D investments (₹1,974 crores) and potential pricing pressures in key segments like respiratory care. While net profit and EPS remain positive, the downward trend in operating efficiency suggests short-term headwinds despite underlying revenue stability.
🔮 Management Outlook & What's Next
Management has emphasized strategic focus on respiratory, oncology, and biosimilars, backed by significant R&D investment of ₹1,974 crores. The company also highlighted ongoing greenfield manufacturing projects and a capital expenditure plan of H 4,000 crores over the past two years. During the AGM, leadership reiterated confidence in long-term growth through innovation and sustainability, with no explicit financial targets provided but clear intent to balance R&D, ESG, and operational excellence.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | 2023-2024 | 2023-2024 | 2024-2025 | 2024-2025 | 2025-2026 |
|---|---|---|---|---|---|
| Equity Capital | 161 | 161 | 162 | 162 | 162 |
| Reserves | 24,664 | 26,545 | 28,201 | 31,032 | 32,757 |
| Borrowings | 674 | 247 | 162 | 92 | 94 |
| Total Liabilities | 6,282 | 5,915 | 6,200 | 6,098 | 7,139 |
| Fixed Assets | 4,819 | 5,069 | 5,119 | 5,262 | 5,503 |
| Investments | 4,181 | 5,319 | 4,849 | 7,792 | 8,061 |
| Total Assets | 31,377 | 32,718 | 34,655 | 37,387 | 40,164 |
The balance sheet reflects a strong equity base of ₹162 crores and growing reserves (₹32,757 crores in 2025-26), indicating retained earnings and financial resilience. Borrowings remain minimal at ₹94 crores, down from ₹162 crores in the prior year, suggesting a deliberate deleveraging trend. Total assets have grown steadily to ₹40,164 crores, driven by investments in manufacturing and R&D, while liabilities remain well-contained, supporting a conservative capital structure.
💰 Cash Flow Statement (₹ Cr)
| Item | 2020-2021 | 2020-2021 |
|---|---|---|
| Operating | +1,587 | +3,755 |
| Investing | -1,964 | -2,387 |
| Financing | +274 | -1,330 |
| Net Cash Flow | — | — |
⚖️ Peer Comparison — Pharmaceuticals & Biotechnology
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 4.51 L Cr | 41.3 | 20.3% | 15.1% | 0.03 |
| Divi's Laboratories Limited | 1.79 L Cr | 72.4 | 22.1% | 16.6% | 0.00 |
| Torrent Pharmaceuticals Limited | 1.49 L Cr | 80.1 | — | — | — |
| Cipla Limited | 1.16 L Cr | 25.4 | 19.4% | 14.6% | 0.00 |
| Dr. Reddy's Laboratories Limited | 1.12 L Cr | 20.0 | 19.7% | 16.6% | 0.12 |
| Lupin Limited | 1.04 L Cr | 36.2 | — | — | — |
| Mankind Pharma Limited | 1.03 L Cr | 49.2 | — | — | — |
| Zydus Lifesciences Limited | 1.02 L Cr | 22.5 | — | — | — |
| Aurobindo Pharma Limited | 87,806 | 25.3 | — | — | — |
| Laurus Labs Limited | 71,455 | 356.8 | — | — | — |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Margin pressure is emerging due to strategic R&D investments and potential pricing or volume softness in core segments, as seen in OPM decline from 28.1% to 17.7% over recent quarters. 2. Geopolitical tensions and supply chain complexities are explicitly flagged as risks, which could impact raw material sourcing and global market access. 3. Regulatory audits pose a persistent compliance risk, especially given the company's global operations and stringent pharma standards. 4. Despite strong reserves, any unexpected capex overruns or delays in greenfield projects could strain liquidity.
📋 Recent Filings
-
Announcement 11 June 2026Cipla announced that the USFDA classified its recent cGMP and Pre-Approval Inspection at the Verna, Goa facility as Voluntary Action Indicated (VAI), ...
-
🔴 annual report 9 June 2026Cipla corrected a filing error regarding the remote e-voting period for its 90th AGM and FY 2025-26 integrated report, changing the end date from 24 J...
-
🟡 Board Meeting 8 June 2026Cipla announced a final dividend of ₹13 per share for FY 2025-26, subject to shareholder approval at the 90th AGM, with tax deducted at source based o...
-
Announcement 2 June 2026Cipla announced its upcoming analyst and institutional investor meeting schedule on June 9, 2026, at its Mumbai office, inviting key investors to disc...
-
🟡 sustainability report 1 June 2026Cipla Limited released its Business Responsibility and Sustainability Report for FY 2025-26 on June 1, 2026, as mandated under SEBI Regulation 34. The...
-
🔴 annual report 1 June 2026Cipla Limited announced its 90th Annual General Meeting (AGM) scheduled for 25 June 2026 at 2:00 p.m. IST via video conferencing, alongside its Integr...
-
Announcement 28 May 2026Cipla announced its upcoming analyst and institutional investor meeting schedule on May 28, 2026, including an in-person session with Citi India on Ju...
-
🟡 Board Meeting 13 May 2026Cipla's board approved convening its 90th Annual General Meeting on 25 June 2026, granted stock options and ESARs under the 2013-A and 2021 schemes, a...
-
🟡 Board Meeting 13 May 2026Cipla announced the outcome of its board meeting held on 13 May 2026, approving the 90th Annual General Meeting on 25 June 2026, granting stock option...
-
🟡 Board Meeting 13 May 2026The board approved convening the 90th Annual General Meeting on 25 June 2026, granted stock options and ESARs under the 2013 and 2021 schemes with spe...
🧠 Analyst's Read
Cipla remains a fundamentally stable player with disciplined governance and a clear strategic direction, but near-term margin trends and execution risks in R&D commercialization warrant close monitoring. Investors should watch for signs of margin recovery and progress in biosimilars or oncology pipelines at upcoming investor updates or AGM discussions.
Based on filing content and financial data. Not a recommendation.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.